Turning mirror-image oligonucleotides into drugs: The evolution of Spiegelmer® therapeutics

Drug Discovery Today

Volumn 20, Issue 1, 2015, Pages 147-155

  Vater, Axel ^a   Klussmann, Sven ^a  

^a NOXXON PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; EMAPTICAP PEGOL; LEXAPTEPID PEGOL; OLAPTESED PEGOL; OLIGONUCLEOTIDE; GENERIC DRUG;

CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; CRYSTAL STRUCTURE; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYDRODYNAMICS; NONHUMAN; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; REVIEW; ANIMAL; CHEMISTRY; DISEASE MODEL;

ANIMALS; APTAMERS, NUCLEOTIDE; DISEASE MODELS, ANIMAL; DRUGS, GENERIC; HUMANS;

EID: 84922431782     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.09.004     Document Type: Review

References (90)

1. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510
2. Ellington, A.D. and Szostak, J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822
3. Robertson, D.L. et al. (1990) Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344, 467-468
4. 2+-binding RNA motifs with an asymmetric purine-rich internal loop and a G-A base pair. RNA 3, 1289-1300
5. Biesecker, G. et al. (1999) Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42, 219-230
6. Guo, K.T. et al. (2006) A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 24, 2220-2231
7. Germer, K. et al. (2013) RNA aptamers and their therapeutic and diagnostic applications. Int. J. Biochem. Mol. Biol. 4, 27-40
8. Keefe, A.D. et al. (2010) Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550
9. Jellinek, D. et al. (1995) Potent 2′-amino-2′deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363-11372
10. FDA. (2004) FDA approves new drug treatment for age-related macular degeneration
11. Syed, B.A. et al. (2012) Wet AMD market. Nat. Rev. Drug Discov. 11, 827
12. Ruckman, J. et al. (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567
13. Tucker, C.E. et al. (1999) Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J. Chromatogr. B: Biomed. Sci. Appl. 732, 203-212
14. Green, L.S. et al. (1996) Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35, 14413-14424
15. Floege, J. et al. (1999) Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154, 169-179
16. Epstein, D. and Kurz, J.C. (2007) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders. PCT/US2007/006020 (WO2007/103549)
17. Rusconi, C.P. et al. (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94
18. Rusconi, C.P. and Tonkens, R.M. (2007) Administration of the REG1 anticoagulation system. PCT/US2007/012625 (WO2007/140000)
19. Ashley, G.W. (1992) Modeling, synthesis and hybridization properties of (L)-ribonucleic acid. J. Am. Chem. Soc. 114, 9731-9736
20. Klussmann, S. et al. (1996) Mirror-image RNA that binds D-adenosine. Nat. Biotechnol. 14, 1112-1115
21. Vallazza, M. et al. (2004) First look at RNA in D-configuration. Acta Crystallogr. D: Biol. Crystallogr. 60, 1-7
22. Bouchard, P.R. et al. (2010) Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 50, 237-257
23. Eulberg, D. et al. (2008) Spiegelmer NOX-E36 for renal diseases. In Therapeutic Oligonucleotides (Kurreck, J., ed.), pp. 200-225, Royal Society of Chemistry
24. Landgraf, G. et al. (2012) Pharmacokinetics, pharmacodynamics, safety and tolerability of the CCL2 antagonist NOX-E36, a novel agent being investigated for treatment of diabetic nephropathy. J. Am. Soc. Nephrol. 23, 960A
25. Haller, H. et al. (2014) CCL2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. 51st ERA-EDTA Congress
26. Kulkarni, O. et al. (2007) Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J. Am. Soc. Nephrol. 18, 2350-2358
27. Kulkarni, O. et al. (2009) Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J. Pharmacol. Exp. Ther. 328, 371-377
28. Ninichuk, V. et al. (2008) Late onset of CCL2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am. J. Pathol. 172, 628-637
29. Darisipudi, M.N. et al. (2011) Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 179, 116-124
30. Baeck, C. et al. (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426
31. Ehling, J. et al. (2014) CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut http://dx.doi.org/10.1136/gutjnl-2013-306294
32. Baeck, C. et al. (2014) Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C macrophage infiltration in mice. Hepatology 59, 1060-1072
33. Schwoebel, F. et al. (2010) Anti-inflammatory effects of the monocyte chemoattractant protein-1 binding Spiegelmer MNOX-E36 in a sub-chronic tobacco smoke induced inflammation model of chronic obstructive pulmonary disease. In C41. Emerging Pharmacology for Chronic Obstructive Pulmonary Disease: Mechanisms and Outcomes. p. A4423, American Thoracic Society
34. Dahal, B.K. et al. (2013) Inhibition of CCL2/MCP-1 by the Spiegelmer mNOX-E36 ameliorates experimental pulmonary hypertension. In C63. Eemperimental Models of Pulmonary Vascular Disease I. p. A4636, American Thoracic Society
35. Vater, A. et al. (2013) Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin. Pharmacol. Ther. 94, 150-157
36. Roccaro, A.M. et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy, Cell Reports, in press.
37. Hinterseer, E. et al. (2013) The Spiegelmer® NOX-A12 abrogates homing of human CLL cells to bone marrow and mobilizes murine CLL cells in the Em-TCL1 transgenic mouse model of CLL. In ASH. p. 4111, American Society of Hematology
38. Liu, S-C. et al. (2014) Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro. Oncol. 16, 21-28
39. Savai, R. et al. (2012) Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 897-908
40. Sayyed, S.G. et al. (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52, 2445-2454
41. Marzorati, S. et al. (2013) Pancreatic islet engraftment is improved by Spiegelmer-based blockade of CXCL12/SDF-1. 12th Congress of the Cell Transplant Society pp. 39 Abstr. 1
42. Ludwig, H. et al. (2013) Anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 alone and in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma: results rrom a Phase IIa study. In ASH. p. 1951, American Society for Hematology
43. Gobbi, M. et al. (2013) Anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 alone and in combination with bendamustine and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL): results from a Phase IIa study. In ASH. p. 1635, American Society for Hematology
44. Schwoebel, F. et al. (2013) The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 121, 2311-2315
45. Riecke, K. et al. (2012) Single and repeated dose first-in-human study with the antihepcidin Spiegelmer NOX-H94. 54th ASH Annual Meeting and Exposition
46. van Eijk, L. et al. (2014) Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood epub ahead of print
47. Sczepanski, J.T. and Joyce, G.F. (2013) Binding of a structured D-RNA molecule by an L-RNA aptamer. J. Am. Chem. Soc. 135, 13290-13293
48. Hoehlig, K. et al. (2013) A Novel C5a-neutralizing mirror-image (L-)aptamer prevents organ failure and improves survival in experimental sepsis. Mol. Ther. 21, 2236-2246
49. Khan, M.A. et al. (2013) Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc. Natl. Acad. Sci. U. S. A. 110, 6061-6066
50. Vater, A. et al. (2013) A mixed mirror-image DNA/RNA aptamer inhibits glucagon and acutely improves glucose tolerance in models of type 1 and type 2 diabetes. J. Biol. Chem. 288, 21136-21147
51. Purschke, W.G. et al. (2014) Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis. Biochem. J. 462, 153-162
52. Schneider, G. et al. (2013) Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy. Mol. Cancer Res. 11, 793-807
53. Maasch, C. et al. (2010) Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J. Biol. Chem. 285, 40012-40018
54. Vater, A. (2004) Tailored SELEX: process for the identification of short aptamers. In Technical Biochemistry. Technische Universität Berlin/Tenea Verlag (in German)
55. Bilik, K.U. et al. (2007) In vitro and in vivo antagonistic action of an anti-amylin Spiegelmer. Neuroreport 18, 1855-1859
56. Denekas, T. et al. (2006) Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br. J. Pharmacol. 148, 536-543
57. Helmling, S. et al. (2004) Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc. Natl. Acad. Sci. U. S. A. 101, 13174-13179
58. Shearman, L.P. et al. (2006) Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147, 1517-1526
59. Sangiao-Alvarellos, S. et al. (2011) Ghrelin neutralization during fasting-refeeding cycle impairs the recuperation of body weight and alters hepatic energy metabolism. Mol. Cell. Endocrinol. 335, 177-188
60. Jarosch, F. (2005) Automated process for the selection of short RNA- and DNA-based Spiegelmers. In Medical Biotechnology. Technische Universität Berlin (in German)
61. Jarosch, F. et al. (2006) In vitro selection using a dual RNA library that allows primerless selection. Nucleic Acids Res. 34, e86
62. Wlotzka, B. et al. (2002) In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Natl. Acad. Sci. U. S. A. 99, 8898-8902
63. Eulberg, D. et al. (2005) Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. Nucleic Acids Res. 33, e45
64. Faulhammer, D. et al. (2004) Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ. RNA 10, 516-527
65. Purschke, W.G. et al. (2003) A DNA Spiegelmer to staphylococcal enterotoxin B. Nucleic Acids Res. 31, 3027-3032
66. Williams, K.P. et al. (1997) Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proc. Natl. Acad. Sci. U. S. A. 94, 11285-11290
67. Purschke, W.G. et al. (2006) An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc. Natl. Acad. Sci. U. S. A. 103, 5173-5178
68. Nolte, A. et al. (1996) Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat. Biotechnol. 14, 1116-1119
69. Vater, A. et al. (2010) Identification and characterisation of C5a-inhibiting biostable aptamers. Mol. Immunol. 47, 2290
70. Weinstock, M.T. et al. (2014) Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity. Proc. Natl. Acad. Sci. U. S. A. 111, 11679-11684
71. Lerner, R.A. (1982) Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature 299, 593-596
72. Boisgard, R. et al. (2005) In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 32, 470-477
73. van Eijk, L. et al. (2013) Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia. Crit. Care 17 (Suppl. 2), P352
74. Hoffmann, S. et al. (2011) RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation. Curr. Protoc. Nucleic Acid Chem. 46, 1-30
75. Eulberg, D. et al. (2006) Spiegelmers for therapeutic applications-use of chiral principles in evolutionary selection techniques. In The Aptamer Handbook (Klussmann, S., ed.), pp. 417-442, Wiley-VCH
76. Turner, J.J. et al. (2011) Methods for L-ribooligonucleotide sequence determination using LCMS. Nucleic Acids Res. 39, e147
77. WHO (2012) International Nonproprietary Names (INN) for Biological and Biotechnological Substances (a review). WHO Document Production Services
78. Hoellenriegel, J. et al. (2013) The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123, 1032-1039
79. Jacamo, R. et al. (2013) SDF-1 inhibition using Spiegelmer® NOX-A12 as a novel strategy for targeting AML cells within their BM microenvironment. In ASH. p. 2454, American Society of Hematology
80. Burger, J.A. and Kipps, T.J. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767
81. Miao, Z. et al. (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U. S. A. 104, 15735-15740
82. Burns, J.M. et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201-2213
83. Fischer, K. et al. (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 29, 3559-3566
84. Brown, J.R. et al. (2013) Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a Phase 1b study. Blood 122, 525
85. Petrucci, M.T. et al. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br. J. Haematol. 160, 649-659
86. Clinicaltrials.gov (2014) NCT01547897: NOX-E36 in patients with type 2 diabetes mellitus and albuminuria
87. NOXXON Pharma AG (2014) NOXXON presents positive results from emapticap pegol Phase IIa diabetic nephropathy study. In Anti-CCL2/MCP-1 Spiegelmer®Emapticap Pegol (NOX-E36) Shows Beneficial and Lasting Effects on Albuminuria and Glycemic Control
88. Gansevoort, R.T. et al. (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382, 339-352
89. Georiev, P. et al. (2014) The anti-hepcidin Siegelmer lexaptepid pegol (NOX-H94) as treatment f anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: a Phase II pilot study. Hematologica 99S1 Abstract P1172
90. Clinicaltrials.gov (2014) NCT01372137: first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NOX-H94